RxDoctor Payments Data

Raabia Ahmad, MD

Cardiovascular Disease · Mountain View, CANPI 1942521497

Payments from drug & device makers

$4,503in general payments, 2019–2025

Across 159 payments — averaging $28.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$757
  • Novartis$607
  • Boehringer Ingelheim$373
  • Novo Nordisk$360
  • Medtronic$351
  • Esperion Therapeutics, Inc.$344
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,503 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$643,605
Medicare patients
1,202
Services billed
4,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin298$423,307
EliquisApixaban273$391,463
EntrestoSacubitril/Valsartan131$175,497
Repatha SureclickEvolocumab131$152,148
OzempicSemaglutide92$114,152
MounjaroTirzepatide86$107,145
FarxigaDapagliflozin Propanediol48$75,199
XareltoRivaroxaban41$61,564
Praluent PenAlirocumab25$19,318
Rosuvastatin Calcium875$15,684
Metoprolol Succinate576$9,645
Valsartan162$6,057
Nebivolol Hcl71$5,973
Torsemide242$5,533
Ezetimibe197$5,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$373$423,307298 claims
PfizerEliquis$102$391,463273 claims
NovartisEntresto$607$175,497131 claims
Novo NordiskOzempic$360$114,15292 claims
AstraZenecaFarxiga$186$75,19948 claims
Johnson & JohnsonXarelto$137$61,56441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →